IDEXX reports 10% third-quarter revenue growth and raises 2026 outlook

By
Stonehaven Analytics
/
Nov 3, 2026

IDEXX Laboratories reported third-quarter 2026 revenue of $1.21 billion, up 10% year on year, driven by strong demand for companion-animal diagnostics and continued adoption of its veterinary technologies. The company also raised its full-year revenue and earnings guidance, reflecting sustained growth in diagnostic testing and expanding instrument installations.

Companion Animal Group diagnostics recurring revenue increased 11% on both a reported and organic basis, with international markets delivering 14% organic growth and the US recording 10%.

IDEXX placed more than 1,900 inVue Dx analysers during the quarter, bringing its installed base to nearly 11,000 instruments. The company also highlighted the expansion of its Cancer Dx testing portfolio and its acquisition of CoVet, an AI-powered clinical assistant designed to improve veterinary workflow efficiency.

Quarterly diluted earnings per share increased 18% to $4.01, while operating margin improved by 100 basis points to 33.1%.

Following the results, IDEXX raised its full-year 2026 revenue forecast to $4.741–4.767 billion and its earnings-per-share outlook to $14.96–15.16.

The performance highlights continued investment in veterinary diagnostics and digital technologies, with recurring testing revenue remaining a key growth driver despite pressures on veterinary practice visits.

"This news service is powered by an AI tool that curates and enhances the content related to animal health. The articles provided are for informational purposes only and should not be considered professional or veterinary advice. The content presented does not reflect the views or opinions of Stonehaven Analytics."

Scroll to Top